2024-512700-18-00招募中2 期
Long-Term Follow-up of Fabry Disease Subjects who were Treated with ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy
Sangamo Therapeutics Inc.1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2025年1月31日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- To evaluate long-term safety of ST-920 by assessment of incidence and severity of adverse events (AEs)
研究概览
简要总结
To evaluate long-term safety of ST-920
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subjects who received ST-920 therapy in a separate parent trial
- •Subjects who have consented to participate in this LTFU study.
排除标准
- •This study has no exclusion criteria
结局指标
主要结局
To evaluate long-term safety of ST-920 by assessment of incidence and severity of adverse events (AEs)
To evaluate long-term safety of ST-920 by assessment of incidence and severity of adverse events (AEs)
次要结局
未报告次要终点
研究者
Clinical Trials Information Desk
Scientific
Sangamo Therapeutics Inc.
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT201) in Subjects with Gaucher Disease (GALILEO-2)2024-511172-33-00Spur Therapeutics Limited1
招募中
2 期
A Study to Assess the Long-Term Efficacy and Safety of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who participated in previous Afimkibart Clinical TrialsAtopic Dermatitis2025-520771-59-00F. Hoffmann-La Roche AG49
Enrolling By Invitation
不适用
"Real-world Assessment of BP Control in Patients With Hypertension by the Netrod RDN System" - REACH-RDNHypertensionNCT07273877Shanghai Golden Leaf MedTec Co. Ltd1,000
已完成
3 期
A Long-Term, Open-Label, Study for Treatment of JIA2023-509651-14-00Pfizer Inc.8
招募中
2 期
Phase I/II Follow-up Study of SAR422459 in Patients with Stargardt’s Macular Degeneration2024-513501-31-00Sanofi-Aventis Recherche & Developpement14